| 2016-10-05 07:06:26|
RDHL 07:06 10/05 10/05/16
RedHill Biopharma initiates Phase II study with Yeliva
RedHill Biopharma announced that a Phase II clinical study evaluating Yeliva in patients with advanced hepatocellular carcinoma, or HCC, has been initiated, with enrollment expected to commence shortly, pending final regulatory clearance. RedHill is pursuing and evaluating with Yeliva multiple clinical programs in oncology, inflammatory and gastrointestinal indications, as well as potential collaboration opportunities with larger pharmaceutical companies to evaluate Yeliva as an add-on therapy to their existing oncology treatments.